Showing results (181-190 of 202) with videos related to
Sort By:
Pageof 21
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|February 5, 2022
Effect of implementation of a 12-dose once-weekly treatment (3HP) in addition to standard regimens to prevent TB on completion rates: Interrupted time series designGonzalo G Alvarez, Kathryn Sullivan, Christopher Pease, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 17, 2013
Cost-effectiveness of newer antiretroviral drugs in treatment-experienced patients with multidrug-resistant HIV diseaseAhmed M Bayoumi, Paul G Barnett, Vilija R Joyce, et al.Trials|September 2, 2022
Enhancing COVID Rehabilitation with Technology (ECORT): protocol for an open-label, single-site randomized controlled trial evaluating the effectiveness of electronic case management for individuals with persistent COVID-19 symptomsSimon Hatcher, Joel Werier, Nicole E Edgar, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 16, 2020
Molecular Epidemiology of Mycobacterium tuberculosis To Describe the Transmission Dynamics Among Inuit Residing in Iqaluit Nunavut Using Whole-Genome SequencingGonzalo G Alvarez, Alice A Zwerling, Carla Duncan, et al.Leukemia|August 24, 2011
TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic propertiesK C Goh, V Novotny-Diermayr, S Hart, et al.Journal of Medicinal Chemistry|February 21, 2012
Discovery of the macrocycle (9E)-15-(2-(pyrrolidin-1-yl)ethoxy)-7,12,25-trioxa-19,21,24-triaza-tetracyclo[18.3.1.1(2,5).1(14,18)]hexacosa-1(24),2,4,9,14(26),15,17,20,22-nonaene (SB1578), a potent inhibitor of janus kinase 2/fms-like tyrosine kinase-3 (JAK2/FLT3) for the treatment of rheumatoid arthritisAnthony D William, Angeline C-H Lee, Anders Poulsen, et al.Journal of Medicinal Chemistry|December 14, 2011
Discovery of kinase spectrum selective macrocycle (16E)-14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene (SB1317/TG02), a potent inhibitor of cyclin dependent kinases (CDKs), Janus kinase 2 (JAK2), and fms-like tyrosine kinase-3 (FLT3) for the treatment of cancerAnthony D William, Angeline C-H Lee, Kee Chuan Goh, et al.Plos One|January 28, 2014
Micronutrient deficiency and treatment adherence in a randomized controlled trial of micronutrient supplementation in ART-naïve persons with HIVLouise Balfour, Johanna N Spaans, Dean Fergusson, et al.Journal of Clinical Medicine|February 27, 2026
Analysis of a Real-World Population Participating in a Cardiac Rehabilitation Program: Cognitive Impairment, Functional Capacity, and Therapy TitrationNicola Virtuoso, Francesca Palmieri, Francesco Loria, et al.The Journal of Pharmacology and Experimental Therapeutics|May 21, 1999
Pharmacological properties of J-104132 (L-753,037), a potent, orally active, mixed ETA/ETB endothelin receptor antagonistM Nishikibe, H Ohta, M Okada, et al.Pageof 21